A successful transplantation, across a positive crossmatch barrier, is one of the most persistent long-standing problems in the field of kidney transplant medicine. The aim of this study was to describe seven consecutive living renal transplantations in recipients with positive crossmatch for donors or positive for donor specific antibodies (DSAs). A preconditioning regimen including plasmapheresis and intravenous immunoglobulin was delivered three times a week until the crossmatch and/or DSAs became negative. Mycophenolate mofetil and tacrolimus were started two days before the plasmapheresis. The protocol was modified to include administration of anti-CD 20 antibody (rituximab, 375 mg/m(2)) from the patient number 3 through the patient nu...
ntroduction: Many candidates for kidney transplantation are highly sensitized (HS) with HLA antibodi...
Desensitization allows successful transplantation of patients with a positive crossmatch (PXM) again...
Background: Intravenous immunoglobulin (IVIG) is used alone and in combination with other therapies ...
Background: Kidney transplantation is associated with improved survival as opposed to long-term dial...
INTRODUCTION: The number of end-stage renal disease (ESRD) patients with preformed antibodies waitin...
Q4Q3Artículo original436-440Introduction. Approximately 10% to 30% of patients on renal transplant w...
OBJECTIVE: Blood group incompatibility in kidney transplants from a living donor can be successful...
none6On all kidney waiting lists the 10% to 20% of patients who have antibodies against more than 80...
BACKGROUND: Traditionally, the presence of antibodies against human leukocyte antigen (HLA)-C and DP...
Renal transplant in highly sensitised patients is associated with increased morbidity. The aim of th...
Background. High-dose IVIG (2 g/kg) alone or low-dose IVIG (100 mg/kg) in conjunction with plasma ex...
RATIONALE: Human leukocyte antigen (HLA) is the major immunologic barrier in kidney transplantatio...
Desensitization regimens including use of intravenous immune globulin and rituximab have been report...
Sensitized patients may reject renal transplants at a tempo or with a force dictated by their previo...
Background/PurposeDesensitization regimens including use of intravenous immune globulin and rituxima...
ntroduction: Many candidates for kidney transplantation are highly sensitized (HS) with HLA antibodi...
Desensitization allows successful transplantation of patients with a positive crossmatch (PXM) again...
Background: Intravenous immunoglobulin (IVIG) is used alone and in combination with other therapies ...
Background: Kidney transplantation is associated with improved survival as opposed to long-term dial...
INTRODUCTION: The number of end-stage renal disease (ESRD) patients with preformed antibodies waitin...
Q4Q3Artículo original436-440Introduction. Approximately 10% to 30% of patients on renal transplant w...
OBJECTIVE: Blood group incompatibility in kidney transplants from a living donor can be successful...
none6On all kidney waiting lists the 10% to 20% of patients who have antibodies against more than 80...
BACKGROUND: Traditionally, the presence of antibodies against human leukocyte antigen (HLA)-C and DP...
Renal transplant in highly sensitised patients is associated with increased morbidity. The aim of th...
Background. High-dose IVIG (2 g/kg) alone or low-dose IVIG (100 mg/kg) in conjunction with plasma ex...
RATIONALE: Human leukocyte antigen (HLA) is the major immunologic barrier in kidney transplantatio...
Desensitization regimens including use of intravenous immune globulin and rituximab have been report...
Sensitized patients may reject renal transplants at a tempo or with a force dictated by their previo...
Background/PurposeDesensitization regimens including use of intravenous immune globulin and rituxima...
ntroduction: Many candidates for kidney transplantation are highly sensitized (HS) with HLA antibodi...
Desensitization allows successful transplantation of patients with a positive crossmatch (PXM) again...
Background: Intravenous immunoglobulin (IVIG) is used alone and in combination with other therapies ...